A Patient-Friendly Guide to MacTel and Encelto (CNTF Implant) Treatment

Macular telangiectasia type 2, commonly called MacTel, is a rare retinal condition that affects the macula, the center of the retina responsible for detailed vision. The retina is the thin layer of nerve tissue lining the back of the eye that captures light and sends visual signals to the brain so we can see. In MacTel, the retina gradually changes over time due to degeneration of specialized retinal support cells and abnormal blood vessel changes around the macula. This can lead to slow, progressive loss of central vision.

Unlike some retinal diseases that mainly involve swelling or bleeding, MacTel is considered a neurodegenerative retinal condition. Over time, the light-sensing cells in the retina and the supporting retinal tissue can become damaged. Patients may develop areas of retinal thinning, changes in retinal pigment, loss of important retinal layers such as the ellipsoid zone, and small cavities within the retina. In some cases, abnormal blood vessels called choroidal neovascularization (CNV) can develop, although this is less common.

Symptoms of MacTel often develop slowly and may initially be subtle. Patients commonly notice blurry central vision, difficulty reading, trouble recognizing faces, missing or distorted areas in vision, or problems with contrast sensitivity. Straight lines may appear bent or parts of words may seem missing while reading. Many patients retain relatively good visual acuity in early disease, but functional vision may still be affected.

Diagnosing MacTel usually requires specialized retinal imaging. Retina specialists commonly use optical coherence tomography (OCT) to evaluate microscopic retinal changes, including ellipsoid zone loss and retinal cavities. Fundus autofluorescence (FAF) can show characteristic changes in macular pigment, and fluorescein angiography may demonstrate abnormal blood vessels or leakage. Specialized imaging helps monitor progression and determine whether complications such as CNV are present.

Historically, treatment options for MacTel were limited because the disease is driven primarily by retinal neurodegeneration rather than fluid or leakage. However, a newer treatment called Encelto (revakinagene taroretcel-lwey) has been developed to help slow disease progression in selected patients with MacTel type 2. Encelto is a small implant placed surgically inside the eye that continuously delivers a neuroprotective factor called ciliary neurotrophic factor (CNTF). The goal of treatment is to slow progression of retinal degeneration and preserve retinal structure for as long as possible.

Encelto does not cure MacTel or restore damaged retinal tissue, but clinical studies suggest it may slow the progression of retinal degeneration, including loss of retinal tissue important for vision. Patients being considered for Encelto often undergo detailed imaging to evaluate disease stage, retinal structure, and eligibility. Some patients may still require anti‑VEGF injections if abnormal blood vessels (CNV) develop as a complication of MacTel.

The Encelto procedure is typically performed in an operating room setting. During surgery, the implant is placed inside the eye to provide long-term release of neuroprotective treatment. Recovery instructions vary by surgeon, but patients are monitored carefully over time using retinal imaging such as OCT and fundus autofluorescence.

Living with MacTel can feel frustrating because symptoms often affect reading and central vision even when standard eye chart vision remains relatively good. Low-vision strategies, magnification tools, improved lighting, and regular follow-up with a retina specialist can help patients maintain independence and quality of life. Because MacTel progresses gradually, early diagnosis and monitoring remain very important.